(0.17%) 5 140.25 points
(0.10%) 38 479 points
(0.28%) 17 896 points
(-0.42%) $83.50
(1.66%) $1.955
(0.15%) $2 350.70
(0.40%) $27.65
(1.31%) $934.20
(-0.02%) $0.935
(-0.13%) $11.01
(-0.16%) $0.799
(1.30%) $93.07
@ $11.63
发出时间: 27 Apr 2024 @ 03:34
回报率: 0.09%
上一信号: Apr 26 - 23:54
上一信号:
回报率: 1.17 %
Live Chart Being Loaded With Signals
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells...
Stats | |
---|---|
今日成交量 | 2.49M |
平均成交量 | 8.85M |
市值 | 3.25B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $-0.450 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.16 |
ATR14 | $0.465 (4.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Vogt Frederick G | Buy | 20 834 | Common Stock |
2024-04-15 | Vogt Frederick G | Sell | 8 851 | Common Stock |
2024-04-15 | Vogt Frederick G | Sell | 20 834 | Restricted Stock Units |
2024-04-15 | Graf Finckenstein Friedrich | Buy | 2 812 | Common Stock |
2024-04-15 | Graf Finckenstein Friedrich | Sell | 1 427 | Common Stock |
INSIDER POWER |
---|
94.66 |
Last 99 transactions |
Buy: 13 607 426 | Sell: 449 378 |
音量 相关性
Iovance Biotherapeutics 相关性 - 货币/商品
Iovance Biotherapeutics 财务报表
Annual | 2023 |
营收: | $1.19M |
毛利润: | $-31.94M (-2 686.12 %) |
EPS: | $-1.890 |
FY | 2023 |
营收: | $1.19M |
毛利润: | $-31.94M (-2 686.12 %) |
EPS: | $-1.890 |
FY | 2022 |
营收: | $0 |
毛利润: | $-21.14M (0.00 %) |
EPS: | $-2.45 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.20 |
Financial Reports:
No articles found.
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。